Transmucosal Drug Delivery Pipeline Report 2023 – Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies – ResearchAndMarkets.com

The “Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update” report has been added to ResearchAndMarkets.com’s offering.

The report provides comprehensive information about the Transmucosal Drug Delivery pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Report Scope

  • Extensive coverage of the Transmucosal Drug Delivery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transmucosal Drug Delivery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

The report enables you to –

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transmucosal Drug Delivery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date 

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Transmucosal Drug Delivery Overview

3 Products under Development

3.1 Pipeline Products by Stage of Development

3.2 Pipeline Products by Segment

3.3 Pipeline Products by Territory

3.4 Pipeline Products by Regulatory Path

3.5 Pipeline Products by Estimated Approval Date

3.6 Ongoing Clinical Trials

4 Transmucosal Drug Delivery – Pipeline Products under Development by Companies

4.1 Transmucosal Drug Delivery Companies – Pipeline Products by Stage of Development

4.2 Transmucosal Drug Delivery – Pipeline Products by Stage of Development

5 Transmucosal Drug Delivery Companies and Product Overview

6 Transmucosal Drug Delivery – Recent Developments

A selection of companies mentioned in this report includes

  • AcelRx Pharmaceuticals Inc
  • AFYX Therapeutics A/S
  • Allergan Ltd
  • Altamira Medica AG
  • Anelleo Inc
  • Aquestive Therapeutics Inc
  • Arovella Therapeutics Ltd
  • ARS Pharmaceuticals, Inc.
  • Atossa Therapeutics Inc
  • Auris Medical AG
  • BeFree!
  • Bespak Europe Ltd
  • Biorings LLC
  • Birmingham Biotech Ltd
  • Bryn Pharma LLC
  • Callitas Therapeutics Inc
  • Chulalongkorn University
  • Conrad
  • Covidrops LLP
  • Dare Bioscience Inc
  • Eledon Pharmaceuticals Inc
  • Emergent BioSolutions Inc
  • EmphyCorp Inc
  • Ena Respiratory Pty Ltd
  • Eureka Therapeutics Inc
  • Eveon SAS
  • Evestra Inc
  • Evofem Biosciences Inc
  • Firebrick Pharma Pty Ltd
  • GeneOne Life Science Inc
  • Ghent University
  • Glenmark Pharmaceuticals Ltd
  • Grasses of Eden Ltd
  • Grunenthal Ltd
  • Halberd Corp
  • Harm Reduction Therapeutics Inc
  • Hebrew University of Jerusalem
  • Hikma Pharmaceuticals Plc
  • Imbed Biosciences Inc
  • IntelGenx Corp
  • ITF Pharma Inc
  • Janssen Sciences Ireland UC
  • Kane Biotech Inc
  • Karessa Pharma AB
  • Karp Lab
  • Kiora Pharmaceuticals Inc
  • Laboratoire HRA Pharma SAS
  • Lachesis Biosciences Ltd
  • Leyden Laboratories BV
  • Lobe Sciences Ltd
  • Lyra Therapeutics Inc
  • MassBiologics
  • McNeil AB
  • Medlab Clinical Ltd
  • Merck & Co Inc
  • Merck Serono SA
  • Mucommune LLC
  • Mystic Pharmaceuticals Inc
  • NorInvent AB
  • Novlead Biotechnology Co Ltd
  • Olfax LLC
  • Opiant Pharmaceuticals Inc
  • OptiNose AS
  • Organon Pharma (UK) Ltd
  • Orion Biotechnology Canada Ltd
  • Orphanse Healthcare SAS
  • Oyster Point Pharma Inc
  • P&B Group
  • Parnell Pharmaceuticals Inc
  • Phoenix Life Sciences International Ltd
  • pHOXBIO Ltd
  • Pocket Naloxone Corp
  • Polyrizon Ltd
  • Receptor Life Sciences Inc
  • Renown Pharmaceuticals Pvt Ltd
  • Rhinomed Ltd
  • Sanotize Research and Development Corp
  • Scientus Pharma Inc
  • Seelos Therapeutics, Inc.
  • Shin Nippon Biomedical Laboratories Ltd
  • SipNose Ltd
  • Starpharma Holdings Ltd
  • The Population Council Inc
  • Therakind Ltd
  • Union Therapeutics AS
  • Virpax Pharmaceuticals Inc
  • VistaGen Therapeutics Inc
  • Wellfully Ltd
  • Xlear Inc
  • Zydus Healthcare Ltd

Source link